Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis

Aliya U. Zaidi, Xiufeng U. Gao, Jennell U. White, Lanetta Bronté-Hall, Alex Glaros, Andrew D. Campbell, Olufunke Y. Martin, Sharon Pennington, Ofelia A. Alvarez, Indryas L. Woldie, Nnamdi Okeke, Patrick C. Hines

Blood (2024) 144 (Supplement 1): 2305.

https://doi.org/10.1182/blood-2024-212284

Published: 2024

Journal Articles

Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)

Jennell U. White, Xiufeng Gao, Kerry Bellemare, Gershwin Theophilus Blyden, Lanetta Bronté-Hall, Alexander K Glaros, Andrew D. Campbell, Olufunke Y. Martin, Sharon Pennington, Ofelia A. Alvarez, Indryas L. Woldie, Nnamdi Okeke, Patrick C. Hines

Blood (2024) 144 (Supplement 1): 3875.

https://doi.org/10.1182/blood-2024-212193

Published: 2024

Journal Articles

Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling Parameters

Kevin H.M. Kuo, Sylvia Titi Singer, Gershwin Theophilus Blyden, Lanetta Bronté-Hall, Aidan Faller, Abdullah Kutlar, Frans A. Kuypers, Aliya U. Zaidi, Patrick C. Hines, Niren Patel, Sandra Larkin, Hanny Al-Samkari, Sujit Sheth, Seyed Mehdi Nouraie, Susan Perrine

Blood (2023) 142 (Supplement 1): 1148.

https://doi.org/10.1182/blood-2023-184627

Published: 2023

Journal Articles

Assessment of Biomarker Response to Clinical Administration of Adakveo in a “Real World” Clinical Setting: A Model for Therapeutic Monitoring in Sickle Cell Disease (SCD)

Jennell White, Corrine Packer-Pencle, Xiufeng Gao, Andrekia Williams-Montgomery, Gershwin Theophilus Blyden, Lanetta Bronté-Hall, Patrick C. Hines

Blood (2023) 142 (Supplement 1): 5282.

https://doi.org/10.1182/blood-2023-191195

Published: 2023

Journal Articles

Healthcare Utilization and Cost of Care Analysis of Patients with Sickle Cell Disease with High Vs. Low Biomarkers: A Retrospective Chart Review

Ryan Dingle, Jennell White, Kerry Bellemare, Lanetta Bronté-Hall, Patrick C. Hines

Blood (2023) 142 (Supplement 1): 5285.

https://doi.org/10.1182/blood-2023-191230

Published: 2023

Journal Articles

Progress: Responsiveness Validation of an Electronic Patient Reported Outcome (ePRO) in Adults with Sickle Cell Disease (NCT05407805)

Caterina P Minniti, Lanetta Bronte-Hall, Shannon Marraffino, Jason Healy, Denis Rybin, David Beidler, Lori Huang, Dana Shelton, Steven Taylor, Colet Goossens, Steven Arkin

Blood (2022) 140 (Supplement 1): 2564–2565.

https://doi.org/10.1182/blood-2022-166368

Published: 2022

Journal Articles

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie

Blood (2021) 138 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2021-149536

Published: 2021

Journal Articles

Whole Blood Adhesion to VCAM-1 and P-Selectin and RBC Mechanical Fragility Can be Compromised in Long COVID-19 Patients with Sickle Cell Disease

Michael Tarasev, Marta Ferranti, Cidney Allen, Xiufeng Gao, Kayla Topping, Marta Ferranti, Biola Makinde-Odesola, Lanetta Bronté-Hall, Patrick Hines

Blood (2021) 138 (Supplement 1): 959.

https://doi.org/10.1182/blood-2021-154308

Published: 2021

Journal Articles

The Benefits Trial of PB-04 to Evaluate Safety, PK, and Preliminary Efficacy in Inducing Fetal Globin Expression in Beta Thalassemia Intermedia and Sickle Cell Disease

Kevin H.M. Kuo, Sylvia Singer, Sujit Sheth, Hanny Al-Samkari, Gershwin Blyden, Lanetta Bronte-Hall, Betty S. Pace, Abdullah Kutlar, Franciscus A. Kuypers, Aidan D Faller, Seyed Mehdi Nouraie, Pramod Terse, Haksong Jin, Xin Xu, Asaf Alimardanov, Arthur J. Sytkowski, Sharie Haugabook, Susan P Perrine

Blood (2021) 138 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2021-148909

Published: 2021

Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140540

Published: 2020

Journal Articles

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

Nirmish Shah, David Beenhouwer, Michael S Broder, MD MSHS, Lanetta Bronte-Hall, Laura De Castro, MD MHSc, Sarah N Gibbs, Victor R Gordeuk, MD, Julie Kanter, MD, Elizabeth S Klings, MD, Thokozeni Lipato, MD, Deepa Manwani, MD, Brigid Scullin, Irina Yermilov, Wally R Smith, MD

Blood (2019) 134 (Supplement_1): 415.

https://doi.org/10.1182/blood-2019-121556

Published: 2019

Journal Articles

How Does Sickle Cell Disease Severity Affect Patient Collection of Disability Insurance and Income: An Analysis of US Survey Data

Jason Shafrin, Howard Z. Thom, Daisy Gaunt, Lauren M. Zhao, George J Joseph, Menaka Bhor, PhD, Avery A. Rizio, Lanetta Bronté-Hall, MPH, MSPH, MD, Nirmish Shah

Blood (2019) 134 (Supplement_1): 5781.

https://doi.org/10.1182/blood-2019-122774

Published: 2019

Journal Articles

Real-World Clinical Burden of Sickle Cell Disease in the US Community-Practice Setting: A Single-Center Experience from the Foundation for Sickle Cell Disease Research

Lanetta Bronté-Hall, MPH, MSPH, MD, Matthew Parkin, Courtney Green, Elsa Tchouambou, DO, Lynn Huynh, MPH, MBA, DrPH, Charu Puri-Sharma, MS, Rose Chang, MSPH, MS, ScD, Anjulika Chawla, MD, James Signorovitch, PhD, Gershwin Theophilus Blyden, MD

Blood (2019) 134 (Supplement_1): 5856.

https://doi.org/10.1182/blood-2019-128700

Published: 2019

Journal Articles

Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States

Howard Z. Thom, Jason Shafrin, Edna Keeney, Lauren M. Zhao, George J Joseph, Menaka Bhor, PhD, Avery A. Rizio, Lanetta Bronté-Hall, MPH, MSPH, MD, Nirmish Shah

Blood (2019) 134 (Supplement_1): 4700.

https://doi.org/10.1182/blood-2019-124132

Published: 2019

NARROW

Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis

Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)

Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling Parameters

Assessment of Biomarker Response to Clinical Administration of Adakveo in a “Real World” Clinical Setting: A Model for Therapeutic Monitoring in Sickle Cell Disease (SCD)

Healthcare Utilization and Cost of Care Analysis of Patients with Sickle Cell Disease with High Vs. Low Biomarkers: A Retrospective Chart Review

Progress: Responsiveness Validation of an Electronic Patient Reported Outcome (ePRO) in Adults with Sickle Cell Disease (NCT05407805)

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Whole Blood Adhesion to VCAM-1 and P-Selectin and RBC Mechanical Fragility Can be Compromised in Long COVID-19 Patients with Sickle Cell Disease

The Benefits Trial of PB-04 to Evaluate Safety, PK, and Preliminary Efficacy in Inducing Fetal Globin Expression in Beta Thalassemia Intermedia and Sickle Cell Disease

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

How Does Sickle Cell Disease Severity Affect Patient Collection of Disability Insurance and Income: An Analysis of US Survey Data

Real-World Clinical Burden of Sickle Cell Disease in the US Community-Practice Setting: A Single-Center Experience from the Foundation for Sickle Cell Disease Research

Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only